Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Exclusives

More »
Dec 30, 2011

2011 IPO Window for Biotechs Lets Through Fewer Companies

Just 13 firms went public compared to 16 in 2010, but discounts were smaller.

2011 IPO Window for Biotechs Lets Through Fewer Companies

Due to market volatility, more firms may go the M&A route rather than flocking to public markets. [© Lane Erickson - Fotolia.com]



Related content

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »